Clinical Trial Update: Ruxolitinib Pre-, During- and Post-HSCT for Patients With Primary or Secondary Myelofibrosis. [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial conducted at Massachusetts General Hospital evaluated ruxolitinib given before, during, and after allogeneic stem cell transplantation …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Myelofibrosis

Drugs mentioned

• Ruxolitinib (ruxolitinib)

Snippet

Sponsor: Massachusetts General Hospital | Conditions: Myelofibrosis | Phase 2 | Status: COMPLETED